Psoriatic Arthritis ICYMI

Key clinical point: Tofacitinib improved dactylitis irrespective of the location and prevented its emergence in the majority of patients with psoriatic arthritis (PsA).

Major finding: In patients with Dactylitis Severity Scores (DSS) > 0, 10 mg tofacitinib twice daily vs placebo led to greater improvements in DSS for feet and other locations at month 1. By month 6, ≤15% of patients with DSS > 0 and <2% of patients with DSS = 0 reported the presence of dactylitis in all digits in the tofacitinib group.

Study details: Findings are from a post hoc analysis of two phase 3 trials including 710 patients with active PsA and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (OPAL Broaden) or tumor necrosis factor inhibitors (OPAL Beyond) and who received 5/10 mg tofacitinib twice daily or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Three authors declared being employees and shareholders of Pfizer. The other authors reported ties with several sources, including Pfizer.

Source: Orbai AM et al. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: Post-hoc analysis of phase III studies. BMC Rheumatol. 2022;6(1):68 (Sep 1). Doi: 10.1186/s41927-022-00298-4

Key clinical point: Tofacitinib improved dactylitis irrespective of the location and prevented its emergence in the majority of patients with psoriatic arthritis (PsA).

Major finding: In patients with Dactylitis Severity Scores (DSS) > 0, 10 mg tofacitinib twice daily vs placebo led to greater improvements in DSS for feet and other locations at month 1. By month 6, ≤15% of patients with DSS > 0 and <2% of patients with DSS = 0 reported the presence of dactylitis in all digits in the tofacitinib group.

Study details: Findings are from a post hoc analysis of two phase 3 trials including 710 patients with active PsA and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (OPAL Broaden) or tumor necrosis factor inhibitors (OPAL Beyond) and who received 5/10 mg tofacitinib twice daily or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Three authors declared being employees and shareholders of Pfizer. The other authors reported ties with several sources, including Pfizer.

Source: Orbai AM et al. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: Post-hoc analysis of phase III studies. BMC Rheumatol. 2022;6(1):68 (Sep 1). Doi: 10.1186/s41927-022-00298-4

Key clinical point: Tofacitinib improved dactylitis irrespective of the location and prevented its emergence in the majority of patients with psoriatic arthritis (PsA).

Major finding: In patients with Dactylitis Severity Scores (DSS) > 0, 10 mg tofacitinib twice daily vs placebo led to greater improvements in DSS for feet and other locations at month 1. By month 6, ≤15% of patients with DSS > 0 and <2% of patients with DSS = 0 reported the presence of dactylitis in all digits in the tofacitinib group.

Study details: Findings are from a post hoc analysis of two phase 3 trials including 710 patients with active PsA and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (OPAL Broaden) or tumor necrosis factor inhibitors (OPAL Beyond) and who received 5/10 mg tofacitinib twice daily or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Three authors declared being employees and shareholders of Pfizer. The other authors reported ties with several sources, including Pfizer.

Source: Orbai AM et al. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: Post-hoc analysis of phase III studies. BMC Rheumatol. 2022;6(1):68 (Sep 1). Doi: 10.1186/s41927-022-00298-4

Key clinical point: Tofacitinib improved dactylitis irrespective of the location and prevented its emergence in the majority of patients with psoriatic arthritis (PsA).

Major finding: In patients with Dactylitis Severity Scores (DSS) > 0, 10 mg tofacitinib twice daily vs placebo led to greater improvements in DSS for feet and other locations at month 1. By month 6, ≤15% of patients with DSS > 0 and <2% of patients with DSS = 0 reported the presence of dactylitis in all digits in the tofacitinib group.

Study details: Findings are from a post hoc analysis of two phase 3 trials including 710 patients with active PsA and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (OPAL Broaden) or tumor necrosis factor inhibitors (OPAL Beyond) and who received 5/10 mg tofacitinib twice daily or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Three authors declared being employees and shareholders of Pfizer. The other authors reported ties with several sources, including Pfizer.

Source: Orbai AM et al. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: Post-hoc analysis of phase III studies. BMC Rheumatol. 2022;6(1):68 (Sep 1). Doi: 10.1186/s41927-022-00298-4

Key clinical point: Tofacitinib improved dactylitis irrespective of the location and prevented its emergence in the majority of patients with psoriatic arthritis (PsA).

Major finding: In patients with Dactylitis Severity Scores (DSS) > 0, 10 mg tofacitinib twice daily vs placebo led to greater improvements in DSS for feet and other locations at month 1. By month 6, ≤15% of patients with DSS > 0 and <2% of patients with DSS = 0 reported the presence of dactylitis in all digits in the tofacitinib group.

Study details: Findings are from a post hoc analysis of two phase 3 trials including 710 patients with active PsA and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (OPAL Broaden) or tumor necrosis factor inhibitors (OPAL Beyond) and who received 5/10 mg tofacitinib twice daily or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Three authors declared being employees and shareholders of Pfizer. The other authors reported ties with several sources, including Pfizer.

Source: Orbai AM et al. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: Post-hoc analysis of phase III studies. BMC Rheumatol. 2022;6(1):68 (Sep 1). Doi: 10.1186/s41927-022-00298-4

Key clinical point: Tofacitinib improved dactylitis irrespective of the location and prevented its emergence in the majority of patients with psoriatic arthritis (PsA).

Major finding: In patients with Dactylitis Severity Scores (DSS) > 0, 10 mg tofacitinib twice daily vs placebo led to greater improvements in DSS for feet and other locations at month 1. By month 6, ≤15% of patients with DSS > 0 and <2% of patients with DSS = 0 reported the presence of dactylitis in all digits in the tofacitinib group.

Study details: Findings are from a post hoc analysis of two phase 3 trials including 710 patients with active PsA and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (OPAL Broaden) or tumor necrosis factor inhibitors (OPAL Beyond) and who received 5/10 mg tofacitinib twice daily or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Three authors declared being employees and shareholders of Pfizer. The other authors reported ties with several sources, including Pfizer.

Source: Orbai AM et al. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: Post-hoc analysis of phase III studies. BMC Rheumatol. 2022;6(1):68 (Sep 1). Doi: 10.1186/s41927-022-00298-4

Key clinical point: Patients with psoriatic arthritis (PsA) who received strategic treatment with biological disease-modifying anti-rheumatic drugs (bDMARD) based on peripheral T-lymphocyte phenotyping achieved greater reduction in disease activity than patients who did not undergo phenotyping or bDMARD selection strategy.

Major finding: A significantly higher proportion of patients in the strategic vs standard bDMARD treatment group achieved disease activity of PsA-remission (90.2% vs 67.8%; P  =  .0132) and minimal disease activity (80.5% vs 60.7%; P  =  .0464) by month 6.

Study details: Findings are from a real-world, retrospective study that included 97 patients with PsA who received bDMARD for ≥1 year and compared 1-year treatment response between the strategic (n = 41) and standard (n = 56) bDMARD treatment groups.

Disclosures: This work was supported by Research on Rare and Intractable Diseases and Research Grant-In-Aid for Scientific Research by the Ministry of Health, Labor, and Welfare of Japan, and other sources. The authors declared receiving grants, honoraria, speaking fees, or consulting fees from several sources.

Source: Miyagawa I et al. Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes. Front Med (Lausanne). 2022;9:934937 (Jul 27). Doi: 10.3389/fmed.2022.934937

Key clinical point: Patients with psoriatic arthritis (PsA) who received strategic treatment with biological disease-modifying anti-rheumatic drugs (bDMARD) based on peripheral T-lymphocyte phenotyping achieved greater reduction in disease activity than patients who did not undergo phenotyping or bDMARD selection strategy.

Major finding: A significantly higher proportion of patients in the strategic vs standard bDMARD treatment group achieved disease activity of PsA-remission (90.2% vs 67.8%; P  =  .0132) and minimal disease activity (80.5% vs 60.7%; P  =  .0464) by month 6.

Study details: Findings are from a real-world, retrospective study that included 97 patients with PsA who received bDMARD for ≥1 year and compared 1-year treatment response between the strategic (n = 41) and standard (n = 56) bDMARD treatment groups.

Disclosures: This work was supported by Research on Rare and Intractable Diseases and Research Grant-In-Aid for Scientific Research by the Ministry of Health, Labor, and Welfare of Japan, and other sources. The authors declared receiving grants, honoraria, speaking fees, or consulting fees from several sources.

Source: Miyagawa I et al. Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes. Front Med (Lausanne). 2022;9:934937 (Jul 27). Doi: 10.3389/fmed.2022.934937

Key clinical point: Patients with psoriatic arthritis (PsA) who received strategic treatment with biological disease-modifying anti-rheumatic drugs (bDMARD) based on peripheral T-lymphocyte phenotyping achieved greater reduction in disease activity than patients who did not undergo phenotyping or bDMARD selection strategy.

Major finding: A significantly higher proportion of patients in the strategic vs standard bDMARD treatment group achieved disease activity of PsA-remission (90.2% vs 67.8%; P  =  .0132) and minimal disease activity (80.5% vs 60.7%; P  =  .0464) by month 6.

Study details: Findings are from a real-world, retrospective study that included 97 patients with PsA who received bDMARD for ≥1 year and compared 1-year treatment response between the strategic (n = 41) and standard (n = 56) bDMARD treatment groups.

Disclosures: This work was supported by Research on Rare and Intractable Diseases and Research Grant-In-Aid for Scientific Research by the Ministry of Health, Labor, and Welfare of Japan, and other sources. The authors declared receiving grants, honoraria, speaking fees, or consulting fees from several sources.

Source: Miyagawa I et al. Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes. Front Med (Lausanne). 2022;9:934937 (Jul 27). Doi: 10.3389/fmed.2022.934937

Key clinical point: Tools like Psoriasis Epidemiology Screening Tool (PEST) and body mass index (BMI) can predict the 2-year risk of developing psoriatic arthritis (PsA) in patients with psoriasis (PsO).

Major finding: Approximately 10% of patients with PsO developed PsA after 2 years. PEST, BMI, modified Rheumatic Disease Comorbidity Index, work status, alcohol use, and fatigue (area under the curve [AUC] 68.9%; sensitivity 82.9%; specificity 48.8%) were most efficient in predicting PsA development; however, another model including only PEST and BMI produced similar results (AUC 68.8%; sensitivity 92.7%; specificity 36.5%).

Study details: The findings are from a prospective cohort study including 1489 patients with PsO and no prior diagnosis of PsA from the CorEvitas Psoriasis Registry who were followed-up for 24 months.

Disclosures: This study was sponsored by CorEvitas, LLC. Three authors declared being employees of CorEvitas, LLC, and the other authors reported ties with several sources, including CorEvitas.

Source: Ogdie A et al. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. J Am Acad Dermatol. 2022 (Aug 17). Doi: 10.1016/j.jaad.2022.07.060

Key clinical point: Tools like Psoriasis Epidemiology Screening Tool (PEST) and body mass index (BMI) can predict the 2-year risk of developing psoriatic arthritis (PsA) in patients with psoriasis (PsO).

Major finding: Approximately 10% of patients with PsO developed PsA after 2 years. PEST, BMI, modified Rheumatic Disease Comorbidity Index, work status, alcohol use, and fatigue (area under the curve [AUC] 68.9%; sensitivity 82.9%; specificity 48.8%) were most efficient in predicting PsA development; however, another model including only PEST and BMI produced similar results (AUC 68.8%; sensitivity 92.7%; specificity 36.5%).

Study details: The findings are from a prospective cohort study including 1489 patients with PsO and no prior diagnosis of PsA from the CorEvitas Psoriasis Registry who were followed-up for 24 months.

Disclosures: This study was sponsored by CorEvitas, LLC. Three authors declared being employees of CorEvitas, LLC, and the other authors reported ties with several sources, including CorEvitas.

Source: Ogdie A et al. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. J Am Acad Dermatol. 2022 (Aug 17). Doi: 10.1016/j.jaad.2022.07.060

Key clinical point: Tools like Psoriasis Epidemiology Screening Tool (PEST) and body mass index (BMI) can predict the 2-year risk of developing psoriatic arthritis (PsA) in patients with psoriasis (PsO).

Major finding: Approximately 10% of patients with PsO developed PsA after 2 years. PEST, BMI, modified Rheumatic Disease Comorbidity Index, work status, alcohol use, and fatigue (area under the curve [AUC] 68.9%; sensitivity 82.9%; specificity 48.8%) were most efficient in predicting PsA development; however, another model including only PEST and BMI produced similar results (AUC 68.8%; sensitivity 92.7%; specificity 36.5%).

Study details: The findings are from a prospective cohort study including 1489 patients with PsO and no prior diagnosis of PsA from the CorEvitas Psoriasis Registry who were followed-up for 24 months.

Disclosures: This study was sponsored by CorEvitas, LLC. Three authors declared being employees of CorEvitas, LLC, and the other authors reported ties with several sources, including CorEvitas.

Source: Ogdie A et al. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. J Am Acad Dermatol. 2022 (Aug 17). Doi: 10.1016/j.jaad.2022.07.060

Key clinical point: Patients with psoriatic arthritis (PsA) who were currently experiencing flares had worse quality of life (QoL), greater disability, and impaired work productivity compared with those who had not experienced flare ever or in the last 12 months.

Major finding: Currently, 168 patients were diagnosed with flare by a physician. Compared with patients who had not experienced flare ever or in the last 12 months, those who were currently experiencing flares had lower QoL scores and higher overall work impairment, disability, and a greater disease impact on patient’s QoL (all P < .01).

Study details: Findings are from the Adelphi PsA Disease Specific Programme, a cross-sectional survey including 2238 patients with PsA and physician-reported flare status data.

Disclosures: The Adelphi SpA IV Disease Specific Programme was funded by Janssen. Two authors declared being employees of Adelphi Real World, and two authors declared being employees of Janssen Pharmaceuticals. The other authors reported receiving research grants and consulting fees from several sources.

Source: Orbai AM et al. Impact of physician-defined flares on quality of life and work impairment: An international survey of 2,238 psoriatic arthritis patients. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.211302

Key clinical point: Patients with psoriatic arthritis (PsA) who were currently experiencing flares had worse quality of life (QoL), greater disability, and impaired work productivity compared with those who had not experienced flare ever or in the last 12 months.

Major finding: Currently, 168 patients were diagnosed with flare by a physician. Compared with patients who had not experienced flare ever or in the last 12 months, those who were currently experiencing flares had lower QoL scores and higher overall work impairment, disability, and a greater disease impact on patient’s QoL (all P < .01).

Study details: Findings are from the Adelphi PsA Disease Specific Programme, a cross-sectional survey including 2238 patients with PsA and physician-reported flare status data.

Disclosures: The Adelphi SpA IV Disease Specific Programme was funded by Janssen. Two authors declared being employees of Adelphi Real World, and two authors declared being employees of Janssen Pharmaceuticals. The other authors reported receiving research grants and consulting fees from several sources.

Source: Orbai AM et al. Impact of physician-defined flares on quality of life and work impairment: An international survey of 2,238 psoriatic arthritis patients. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.211302

Key clinical point: Patients with psoriatic arthritis (PsA) who were currently experiencing flares had worse quality of life (QoL), greater disability, and impaired work productivity compared with those who had not experienced flare ever or in the last 12 months.

Major finding: Currently, 168 patients were diagnosed with flare by a physician. Compared with patients who had not experienced flare ever or in the last 12 months, those who were currently experiencing flares had lower QoL scores and higher overall work impairment, disability, and a greater disease impact on patient’s QoL (all P < .01).

Study details: Findings are from the Adelphi PsA Disease Specific Programme, a cross-sectional survey including 2238 patients with PsA and physician-reported flare status data.

Disclosures: The Adelphi SpA IV Disease Specific Programme was funded by Janssen. Two authors declared being employees of Adelphi Real World, and two authors declared being employees of Janssen Pharmaceuticals. The other authors reported receiving research grants and consulting fees from several sources.

Source: Orbai AM et al. Impact of physician-defined flares on quality of life and work impairment: An international survey of 2,238 psoriatic arthritis patients. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.211302

Key clinical point: Methotrexate (MTX)-related side effects were more prevalent in patients with psoriatic arthritis (PsA) vs rheumatoid arthritis (RA), whereas tumor necrosis factor inhibitor (TNFi)-related side effects were equally prevalent in patients with PsA and RA.

Major finding: In the first year, a higher proportion of patients with PsA vs RA reported MTX-related side effects (44.8% vs 29.4%), but similar proportions of patients with PsA (24.2%) and RA (22.8%) reported TNFi-related side effects. Patients with PsA vs RA were 1.8 times more likely to experience side effects with MTX (odds ratio 1.77; 95% CI 1.21-2.60).

Study details: Findings are from a retrospective cohort study including new initiators of MTX (PsA: n = 116 and RA: n = 4247) and TNFi (PsA: n = 124 and RA: n = 4361).

Disclosures: This study was funded by Amgen Inc. Two authors declared being employees or owning stocks in Amgen. The other authors declared receiving grants, funding, honoraria, or consulting fees from several sources, including Amgen.

Source: Ogdie A et al. Side effects of methotrexate and tumor necrosis factor inhibitors: Differences in tolerability among patients with psoriatic arthritis and rheumatoid arthritis. ACR Open Rheumatol. 2022 (Aug 15). Doi: 10.1002/acr2.11467

Key clinical point: Methotrexate (MTX)-related side effects were more prevalent in patients with psoriatic arthritis (PsA) vs rheumatoid arthritis (RA), whereas tumor necrosis factor inhibitor (TNFi)-related side effects were equally prevalent in patients with PsA and RA.

Major finding: In the first year, a higher proportion of patients with PsA vs RA reported MTX-related side effects (44.8% vs 29.4%), but similar proportions of patients with PsA (24.2%) and RA (22.8%) reported TNFi-related side effects. Patients with PsA vs RA were 1.8 times more likely to experience side effects with MTX (odds ratio 1.77; 95% CI 1.21-2.60).

Study details: Findings are from a retrospective cohort study including new initiators of MTX (PsA: n = 116 and RA: n = 4247) and TNFi (PsA: n = 124 and RA: n = 4361).

Disclosures: This study was funded by Amgen Inc. Two authors declared being employees or owning stocks in Amgen. The other authors declared receiving grants, funding, honoraria, or consulting fees from several sources, including Amgen.

Source: Ogdie A et al. Side effects of methotrexate and tumor necrosis factor inhibitors: Differences in tolerability among patients with psoriatic arthritis and rheumatoid arthritis. ACR Open Rheumatol. 2022 (Aug 15). Doi: 10.1002/acr2.11467

Key clinical point: Methotrexate (MTX)-related side effects were more prevalent in patients with psoriatic arthritis (PsA) vs rheumatoid arthritis (RA), whereas tumor necrosis factor inhibitor (TNFi)-related side effects were equally prevalent in patients with PsA and RA.

Major finding: In the first year, a higher proportion of patients with PsA vs RA reported MTX-related side effects (44.8% vs 29.4%), but similar proportions of patients with PsA (24.2%) and RA (22.8%) reported TNFi-related side effects. Patients with PsA vs RA were 1.8 times more likely to experience side effects with MTX (odds ratio 1.77; 95% CI 1.21-2.60).

Study details: Findings are from a retrospective cohort study including new initiators of MTX (PsA: n = 116 and RA: n = 4247) and TNFi (PsA: n = 124 and RA: n = 4361).

Disclosures: This study was funded by Amgen Inc. Two authors declared being employees or owning stocks in Amgen. The other authors declared receiving grants, funding, honoraria, or consulting fees from several sources, including Amgen.

Source: Ogdie A et al. Side effects of methotrexate and tumor necrosis factor inhibitors: Differences in tolerability among patients with psoriatic arthritis and rheumatoid arthritis. ACR Open Rheumatol. 2022 (Aug 15). Doi: 10.1002/acr2.11467

Key clinical point: Among patients with psoriatic arthritis (PsA) women experienced significantly higher disease burden than men despite similar disease activity and comparable treatments.

Major finding: Despite similar disease duration (P  =  .42), disease presentation, and biologic use (P  =  .38), women vs men had worse mean quality-of-life (0.80 vs 0.82; P  =  .02) and disability and physical functioning (0.56 vs 0.41; P < .01) scores, greater degree of work activity impairment (27.9% vs 24.6%; P < .01), and higher pain and fatigue scores (P < .01).

Study details: This study analyzed the data of 2270 patients with PsA (1223 men and 1047 women) from the Adelphi PsA Disease Specific Programme.

Disclosures: This study was funded by Janssen Research & Development, LLC. Three authors declared being employees of Janssen and owning stocks in Janssen/Johnson and Johnson. Some authors declared receiving research grants and consulting fees from several sources, including Janssen.

Source: Gossec L et al. Women with psoriatic arthritis experience higher disease burden than men: Findings from a real-world survey in the USA and Europe. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.220154

Key clinical point: Among patients with psoriatic arthritis (PsA) women experienced significantly higher disease burden than men despite similar disease activity and comparable treatments.

Major finding: Despite similar disease duration (P  =  .42), disease presentation, and biologic use (P  =  .38), women vs men had worse mean quality-of-life (0.80 vs 0.82; P  =  .02) and disability and physical functioning (0.56 vs 0.41; P < .01) scores, greater degree of work activity impairment (27.9% vs 24.6%; P < .01), and higher pain and fatigue scores (P < .01).

Study details: This study analyzed the data of 2270 patients with PsA (1223 men and 1047 women) from the Adelphi PsA Disease Specific Programme.

Disclosures: This study was funded by Janssen Research & Development, LLC. Three authors declared being employees of Janssen and owning stocks in Janssen/Johnson and Johnson. Some authors declared receiving research grants and consulting fees from several sources, including Janssen.

Source: Gossec L et al. Women with psoriatic arthritis experience higher disease burden than men: Findings from a real-world survey in the USA and Europe. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.220154

Key clinical point: Among patients with psoriatic arthritis (PsA) women experienced significantly higher disease burden than men despite similar disease activity and comparable treatments.

Major finding: Despite similar disease duration (P  =  .42), disease presentation, and biologic use (P  =  .38), women vs men had worse mean quality-of-life (0.80 vs 0.82; P  =  .02) and disability and physical functioning (0.56 vs 0.41; P < .01) scores, greater degree of work activity impairment (27.9% vs 24.6%; P < .01), and higher pain and fatigue scores (P < .01).

Study details: This study analyzed the data of 2270 patients with PsA (1223 men and 1047 women) from the Adelphi PsA Disease Specific Programme.

Disclosures: This study was funded by Janssen Research & Development, LLC. Three authors declared being employees of Janssen and owning stocks in Janssen/Johnson and Johnson. Some authors declared receiving research grants and consulting fees from several sources, including Janssen.

Source: Gossec L et al. Women with psoriatic arthritis experience higher disease burden than men: Findings from a real-world survey in the USA and Europe. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.220154

Key clinical point: Among patients with psoriatic arthritis (PsA) women experienced significantly higher disease burden than men despite similar disease activity and comparable treatments.

Major finding: Despite similar disease duration (P  =  .42), disease presentation, and biologic use (P  =  .38), women vs men had worse mean quality-of-life (0.80 vs 0.82; P  =  .02) and disability and physical functioning (0.56 vs 0.41; P < .01) scores, greater degree of work activity impairment (27.9% vs 24.6%; P < .01), and higher pain and fatigue scores (P < .01).

Study details: This study analyzed the data of 2270 patients with PsA (1223 men and 1047 women) from the Adelphi PsA Disease Specific Programme.

Disclosures: This study was funded by Janssen Research & Development, LLC. Three authors declared being employees of Janssen and owning stocks in Janssen/Johnson and Johnson. Some authors declared receiving research grants and consulting fees from several sources, including Janssen.

Source: Gossec L et al. Women with psoriatic arthritis experience higher disease burden than men: Findings from a real-world survey in the USA and Europe. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.220154

Key clinical point: Among patients with psoriatic arthritis (PsA) women experienced significantly higher disease burden than men despite similar disease activity and comparable treatments.

Major finding: Despite similar disease duration (P  =  .42), disease presentation, and biologic use (P  =  .38), women vs men had worse mean quality-of-life (0.80 vs 0.82; P  =  .02) and disability and physical functioning (0.56 vs 0.41; P < .01) scores, greater degree of work activity impairment (27.9% vs 24.6%; P < .01), and higher pain and fatigue scores (P < .01).

Study details: This study analyzed the data of 2270 patients with PsA (1223 men and 1047 women) from the Adelphi PsA Disease Specific Programme.

Disclosures: This study was funded by Janssen Research & Development, LLC. Three authors declared being employees of Janssen and owning stocks in Janssen/Johnson and Johnson. Some authors declared receiving research grants and consulting fees from several sources, including Janssen.

Source: Gossec L et al. Women with psoriatic arthritis experience higher disease burden than men: Findings from a real-world survey in the USA and Europe. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.220154

Key clinical point: Among patients with psoriatic arthritis (PsA) women experienced significantly higher disease burden than men despite similar disease activity and comparable treatments.

Major finding: Despite similar disease duration (P  =  .42), disease presentation, and biologic use (P  =  .38), women vs men had worse mean quality-of-life (0.80 vs 0.82; P  =  .02) and disability and physical functioning (0.56 vs 0.41; P < .01) scores, greater degree of work activity impairment (27.9% vs 24.6%; P < .01), and higher pain and fatigue scores (P < .01).

Study details: This study analyzed the data of 2270 patients with PsA (1223 men and 1047 women) from the Adelphi PsA Disease Specific Programme.

Disclosures: This study was funded by Janssen Research & Development, LLC. Three authors declared being employees of Janssen and owning stocks in Janssen/Johnson and Johnson. Some authors declared receiving research grants and consulting fees from several sources, including Janssen.

Source: Gossec L et al. Women with psoriatic arthritis experience higher disease burden than men: Findings from a real-world survey in the USA and Europe. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.220154

Key clinical point: Levels of C-reactive protein (CRP), a classic inflammatory marker, do not adequately reflect the level of disease activity (DA) in patients with psoriatic arthritis (PsA).

Major finding: CRP status was only associated with the erythrocyte sedimentation rate (odds ratio 1.04; P  =  .005) and not with any DA-related parameter. Among patients with normal CRP levels, a substantial proportion (45.9%) of patients were in non-minimal DA state, with 21.2% having moderate DA and 5.9% having high DA.

Study details: Findings are from a cross-sectional study including 128 patients with PsA, of which 66.4% had normal CRP levels (≤0.5 mg/dL) and the remaining had high CRP levels (>0.5 mg/dL).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Gialouri CG et al. Normal C-reactive protein in active psoriatic arthritis: Results from real-world clinical practice. Ther Adv Musculoskelet Dis. 2022 (Sep 5). Doi: 10.1177/1759720X221122417

Key clinical point: Levels of C-reactive protein (CRP), a classic inflammatory marker, do not adequately reflect the level of disease activity (DA) in patients with psoriatic arthritis (PsA).

Major finding: CRP status was only associated with the erythrocyte sedimentation rate (odds ratio 1.04; P  =  .005) and not with any DA-related parameter. Among patients with normal CRP levels, a substantial proportion (45.9%) of patients were in non-minimal DA state, with 21.2% having moderate DA and 5.9% having high DA.

Study details: Findings are from a cross-sectional study including 128 patients with PsA, of which 66.4% had normal CRP levels (≤0.5 mg/dL) and the remaining had high CRP levels (>0.5 mg/dL).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Gialouri CG et al. Normal C-reactive protein in active psoriatic arthritis: Results from real-world clinical practice. Ther Adv Musculoskelet Dis. 2022 (Sep 5). Doi: 10.1177/1759720X221122417

Key clinical point: Levels of C-reactive protein (CRP), a classic inflammatory marker, do not adequately reflect the level of disease activity (DA) in patients with psoriatic arthritis (PsA).

Major finding: CRP status was only associated with the erythrocyte sedimentation rate (odds ratio 1.04; P  =  .005) and not with any DA-related parameter. Among patients with normal CRP levels, a substantial proportion (45.9%) of patients were in non-minimal DA state, with 21.2% having moderate DA and 5.9% having high DA.

Study details: Findings are from a cross-sectional study including 128 patients with PsA, of which 66.4% had normal CRP levels (≤0.5 mg/dL) and the remaining had high CRP levels (>0.5 mg/dL).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Gialouri CG et al. Normal C-reactive protein in active psoriatic arthritis: Results from real-world clinical practice. Ther Adv Musculoskelet Dis. 2022 (Sep 5). Doi: 10.1177/1759720X221122417

Key clinical point: Levels of C-reactive protein (CRP), a classic inflammatory marker, do not adequately reflect the level of disease activity (DA) in patients with psoriatic arthritis (PsA).

Major finding: CRP status was only associated with the erythrocyte sedimentation rate (odds ratio 1.04; P  =  .005) and not with any DA-related parameter. Among patients with normal CRP levels, a substantial proportion (45.9%) of patients were in non-minimal DA state, with 21.2% having moderate DA and 5.9% having high DA.

Study details: Findings are from a cross-sectional study including 128 patients with PsA, of which 66.4% had normal CRP levels (≤0.5mg/dL) and the remaining had high CRP levels (>0.5mg/dL).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Gialouri CG et al. Normal C-reactive protein in active psoriatic arthritis: Results from real-world clinical practice. Ther Adv Musculoskelet Dis. 2022 (Sep 5). Doi: 10.1177/1759720X221122417

Key clinical point: Levels of C-reactive protein (CRP), a classic inflammatory marker, do not adequately reflect the level of disease activity (DA) in patients with psoriatic arthritis (PsA).

Major finding: CRP status was only associated with the erythrocyte sedimentation rate (odds ratio 1.04; P  =  .005) and not with any DA-related parameter. Among patients with normal CRP levels, a substantial proportion (45.9%) of patients were in non-minimal DA state, with 21.2% having moderate DA and 5.9% having high DA.

Study details: Findings are from a cross-sectional study including 128 patients with PsA, of which 66.4% had normal CRP levels (≤0.5mg/dL) and the remaining had high CRP levels (>0.5mg/dL).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Gialouri CG et al. Normal C-reactive protein in active psoriatic arthritis: Results from real-world clinical practice. Ther Adv Musculoskelet Dis. 2022 (Sep 5). Doi: 10.1177/1759720X221122417

Key clinical point: Levels of C-reactive protein (CRP), a classic inflammatory marker, do not adequately reflect the level of disease activity (DA) in patients with psoriatic arthritis (PsA).

Major finding: CRP status was only associated with the erythrocyte sedimentation rate (odds ratio 1.04; P  =  .005) and not with any DA-related parameter. Among patients with normal CRP levels, a substantial proportion (45.9%) of patients were in non-minimal DA state, with 21.2% having moderate DA and 5.9% having high DA.

Study details: Findings are from a cross-sectional study including 128 patients with PsA, of which 66.4% had normal CRP levels (≤0.5mg/dL) and the remaining had high CRP levels (>0.5mg/dL).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Gialouri CG et al. Normal C-reactive protein in active psoriatic arthritis: Results from real-world clinical practice. Ther Adv Musculoskelet Dis. 2022 (Sep 5). Doi: 10.1177/1759720X221122417